CytomX Therapeutics, Inc.CTMXEarnings & Financial Report
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Revenue
$33.4M
Gross Profit
N/A
Operating Profit
$4.1M
Net Profit
$5.7M
Gross Margin
N/A
Operating Margin
12.3%
Net Margin
17.2%
YoY Growth
26.7%
CytomX Therapeutics, Inc. Q3 FY2024 Financial Summary
CytomX Therapeutics, Inc. reported revenue of $33.4M (up 26.7% YoY) for Q3 FY2024, with a net profit of $5.7M (up 91.7% YoY) (17.2% margin).
Key Financial Metrics
| Total Revenue | $33.4M |
|---|---|
| Net Profit | $5.7M |
| Gross Margin | N/A |
| Operating Margin | 12.3% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
CytomX Therapeutics, Inc. Q3 FY2024 revenue of $33.4M breaks down across 4 segments, led by Bristol Myers Squibb Company at $23.0M (68.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Bristol Myers Squibb Company | $23.0M | 68.7% |
| Modernatx Inc | $5.8M | 17.3% |
| Regeneron Pharmaceuticals Inc | $2.9M | 8.7% |
| Other | $1.8M | 5.3% |
CytomX Therapeutics, Inc. Revenue by Segment — Quarterly Trend
CytomX Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Bristol Myers Squibb Company and Modernatx Inc) has evolved quarter over quarter.
| Segment | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|---|
| Bristol Myers Squibb Company | $11.6M | $30.4M | $21.9M | $23.0M |
| Modernatx Inc | — | — | — | $5.8M |
| Regeneron Pharmaceuticals Inc | $2.1M | $1.6M | $2.9M | $2.9M |
| Other | — | $9.5M | $7.4M | $1.8M |
CytomX Therapeutics, Inc. Annual Revenue by Year
CytomX Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $138.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $138.1M |
| 2023 | $101.2M |
| 2022 | $53.2M |
CytomX Therapeutics, Inc. Quarterly Revenue & Net Profit History
CytomX Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $18.7M | -25.7% | $-154.0K | -0.8% |
| Q1 FY2025 | $50.9M | +22.8% | $23.5M | 46.2% |
| Q4 FY2024 | $38.1M | +43.2% | $18.9M | 49.6% |
| Q3 FY2024 | $33.4M | +26.7% | $5.7M | 17.2% |
| Q2 FY2024 | $25.1M | +1.6% | $-6.5M | -26.0% |
| Q1 FY2024 | $41.5M | +76.4% | $13.8M | 33.3% |
| Q4 FY2023 | $26.6M | +32.2% | $837.0K | 3.1% |
| Q3 FY2023 | $26.4M | +136.7% | $3.0M | 11.3% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.4M | $26.6M | $41.5M | $25.1M | $33.4M | $38.1M | $50.9M | $18.7M |
| YoY Growth | 136.7% | 32.2% | 76.4% | 1.6% | 26.7% | 43.2% | 22.8% | -25.7% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $221.2M | $201.8M | $184.7M | $159.2M | $139.0M | $120.5M | $98.5M | $175.1M |
| Liabilities | $272.4M | $249.2M | $216.4M | $190.4M | $162.4M | $121.0M | $73.4M | $55.1M |
| Equity | $-51.2M | $-47.4M | $-31.7M | $-31.2M | $-23.5M | $-456000 | $25.0M | $119.9M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-18.2M | $-22.0M | $-26.0M | $-19.5M | $-20.7M | $-19.9M | $-21.0M | $-15.8M |